Fat Content in Liver and Skeletal Muscle Changes in a Reciprocal Manner in Patients with Acromegaly during Combination Therapy with a Somatostatin Analog and a GH Receptor Antagonist: A Randomized Clinical Trial

被引:38
作者
Madsen, Michael [1 ]
Krusenstjerna-Hafstrom, Thomas [2 ]
Moller, Louise [1 ]
Christensen, Britt [1 ]
Vendelbo, Mikkel Holm [1 ]
Pedersen, Steen B. [1 ]
Frystyk, Jan [1 ]
Jessen, Niels [1 ]
Hansen, Troels Krarup [1 ]
Stodkilde-Jorgensen, Hans [3 ]
Flyvbjerg, Allan [1 ]
Jorgensen, Jens Otto L. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Internal Med & Endocrinol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Pediat, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, Magnet Resonance Res Ctr, DK-8000 Aarhus C, Denmark
基金
英国医学研究理事会;
关键词
GROWTH-HORMONE DEFICIENCY; INSULIN-RESISTANCE; NONALCOHOLIC STEATOHEPATITIS; RESONANCE SPECTROSCOPY; ECTOPIC FAT; HUMAN SERUM; FACTOR-I; PEGVISOMANT; HEALTHY; GLUCOSE;
D O I
10.1210/jc.2011-2681
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Pegvisomant is a GH antagonist, which is used for the treatment of acromegalic patients. It effectively blocks the hepatic and peripheral effects of GH, but transient elevations in circulating liver enzymes of unknown pathogenesis may occur, which seems to be more prevalent when the treatment is combined with a somatostatin analog (SA). Accumulation of intrahepatic lipid is a known cause of elevated liver enzymes, and there is evidence to suggest that GH impacts lipid content in liver and skeletal muscle. Objective: Our objective was to measure lipid content in liver and skeletal muscle in acromegalic patients before and after cotreatment with pegvisomant and SA as compared with SA monotherapy. Design: Eighteen acromegalic patients well controlled on SA monotherapy were randomized in a parallel study over 24 wk to 1) unchanged SA monotherapy, or 2) cotreatment with pegvisomant (15-30 mg twice a week) and SA (half the usual dosage). Setting: This was an investigator-initiated study in a single tertiary referral center. Main Outcome Measures: Intrahepatic lipid (IHL) and intramyocellular lipid (IMCL) was assessed by H-1 magnetic resonance spectroscopy. Results: IHL increased in the cotreatment group compared with SA only (P = 0.002). The increase was positively correlated to weekly pegvisomant dose (r(2) = 0.52; P = 0.01). By contrast, IMCL decreased in the cotreatment group compared with SA only (P = 0.01). These changes related neither to insulin sensitivity nor inflammatory markers. Conclusion: Cotreatment with pegvisomant and a reduced SA dose increase IHL and decrease IMCL compared with SA monotherapy. The clinical implications remain unclear, but increased IHL may be causally linked to the transient elevations in liver enzymes observed during pegvisomant treatment. (J Clin Endocrinol Metab 97: 1227-1235, 2012)
引用
收藏
页码:1227 / 1235
页数:9
相关论文
共 41 条
[1]   Gender differences of oligomers and total adiponectin during puberty: A cross-sectional study of 859 Danish school children [J].
Andersen, Kristian Kjaer ;
Frystyk, Jan ;
Wolthers, Ole D. ;
Heuck, Carsten ;
Flyvbjerg, Allan .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (05) :1857-1862
[2]   GH-Dependent STAT5 Signaling Plays an Important Role in Hepatic Lipid Metabolism [J].
Barclay, Johanna L. ;
Nelson, Caroline N. ;
Ishikawa, Mayumi ;
Murray, Lauren A. ;
Kerr, Linda M. ;
McPhee, Timothy R. ;
Powell, Elizabeth E. ;
Waters, Michael J. .
ENDOCRINOLOGY, 2011, 152 (01) :181-192
[3]   Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis [J].
Biering, H ;
Saller, B ;
Bauditz, J ;
Pirlich, M ;
Rudolph, B ;
Johne, A ;
Buchfelder, M ;
Mann, K ;
Droste, M ;
Schreiber, T ;
Lochs, H ;
Strasburger, CJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (02) :213-220
[4]   A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum [J].
Chen, JW ;
Ledet, T ;
Orskov, H ;
Jessen, N ;
Lund, S ;
Whittaker, J ;
De Meyts, P ;
Larsen, MB ;
Christiansen, JS ;
Frystyk, J .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (06) :E1149-E1155
[5]  
Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x
[6]   Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA [J].
De Marinis, Laura ;
Bianchi, Antonio ;
Fusco, Alessandra ;
Cimino, Vincenzo ;
Mormando, Marilda ;
Tilaro, Laura ;
Mazziotti, Gherardo ;
Pontecorvi, Alfredo ;
Giustina, Andrea .
PITUITARY, 2007, 10 (03) :227-232
[7]   Supraphysiological growth hormone:: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults [J].
Ehrnborg, C ;
Ellegård, L ;
Bosaeus, I ;
Bengtsson, BÅ ;
Rosén, T .
CLINICAL ENDOCRINOLOGY, 2005, 62 (04) :449-457
[8]   Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly [J].
Feenstra, J ;
de Herder, WW ;
ten Have, SMTH ;
van den Beld, AW ;
Feelders, RA ;
Janssen, JAMJL ;
van der Lely, AJ .
LANCET, 2005, 365 (9471) :1644-1646
[9]   Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant [J].
Feenstra, J ;
van Aken, MO ;
de Herder, WW ;
Feelders, RA ;
van der Lely, AJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (06) :805-806
[10]   Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly [J].
Freda, Pamela U. ;
Shen, Wei ;
Heymsfield, Steven B. ;
Reyes-Vidal, Carlos M. ;
Geer, Eliza B. ;
Bruce, Jeffrey N. ;
Gallagher, Dympna .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06) :2334-2343